drugset / Trial / NCT03093740
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
Non-randomizedSingle-groupOpen-labelPrevention
Summary
Open label single center study for the donation of HCV positive kidneys to HCV negative recipients with interventional treatment to prevent HCV transmission upon transplantation.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2020-12-31
- Completion
- 2021-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sofosbuvir | Small molecule | — | — |
| Subject | Zepatier | Other / unclassified | — | — |